Trial Profile
A Phase II Study of Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Epithelial Ovarian/Fallopian Tube/ Primary Peritoneal Carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Vinorelbine (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 17 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 22 Feb 2012 Actual initiation date (January 2011) added as reported by ClinicalTrials.gov.
- 22 Feb 2012 Planned End Date changed from 1 Sep 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.